185 related articles for article (PubMed ID: 26462895)
21. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
22. Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).
Agresti R; Martelli G; Sandri M; Tagliabue E; Carcangiu ML; Maugeri I; Pellitteri C; Ferraris C; Capri G; Moliterni A; Bianchi G; Mariani G; Trecate G; Lozza L; Langer M; Rampa M; Gennaro M; Greco M; Menard S; Pierotti MA
Cancer; 2014 Mar; 120(6):885-93. PubMed ID: 24323615
[TBL] [Abstract][Full Text] [Related]
23. [Adenoid cystic carcinoma of the breast:report of 25 cases].
Wei L; Liang X; Li S; Liu J
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):147-50. PubMed ID: 24796466
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
25. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
26. c-erbB-2 status is an independent predictor of survival after first recurrence.
Horiguchi J; Iino Y; Takei H; Maemura M; Takeyoshi I; Yokoe T; Ohwada S; Oyama T; Nakajima T; Morishita Y
Int J Oncol; 1998 Jan; 12(1):123-8. PubMed ID: 9454895
[TBL] [Abstract][Full Text] [Related]
27. Pure and Mixed Tubular Carcinoma of the Breast: Mammographic Features, Clinicopathological Characteristics and Prognostic Analysis.
Wen C; Xu W; Qin G; Zeng H; He Z; Wang S; Xu Z; Ma M; Luo Z; Chen W
Technol Cancer Res Treat; 2021; 20():15330338211045198. PubMed ID: 34918991
[No Abstract] [Full Text] [Related]
28. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer.
Kilickap S; Kaya Y; Yucel B; Tuncer E; Babacan NA; Elagoz S
Asian Pac J Cancer Prev; 2014; 15(3):1381-5. PubMed ID: 24606469
[TBL] [Abstract][Full Text] [Related]
29. Prognostic implication of the primary tumor location in early-stage breast cancer: focus on lower inner zone.
Yang J; Tang S; Zhou Y; Qiu J; Zhang J; Zhu S; Lv Q
Breast Cancer; 2018 Jan; 25(1):100-107. PubMed ID: 28822078
[TBL] [Abstract][Full Text] [Related]
30. Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
Lu K; Li H; Wu Z; Liu D; Ye H; Xu L; Liu Y
J BUON; 2018; 23(5):1297-1301. PubMed ID: 30570850
[TBL] [Abstract][Full Text] [Related]
31. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
32. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
Shahi KS; Bhandari G; Singh A
J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
[TBL] [Abstract][Full Text] [Related]
33. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer in young women: prognostic factors and clinicopathological features.
Aryandono T; Harijadi ; Soeripto
Asian Pac J Cancer Prev; 2006; 7(3):451-4. PubMed ID: 17059343
[TBL] [Abstract][Full Text] [Related]
36. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
[TBL] [Abstract][Full Text] [Related]
37. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
[TBL] [Abstract][Full Text] [Related]
38. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of preoperative
Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
[TBL] [Abstract][Full Text] [Related]
40. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
